The purpose of the study is to evaluate the effectiveness of selpercatinib in patients who have early-stage RET fusion-positive NSCLC and have already undergone surgery or radiation treatment. Participants in the study will be randomly assigned to receive either selpercatinib or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will be monitored to assess the progression of their condition and any potential side effects of the treatment. The trial aims to provide valuable information on whether selpercatinib can improve outcomes for patients with this specific type of lung cancer. The study is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.

The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

The purpose of the study is to determine whether stopping long‑term aspirin in this population is not worse than continuing it for overall health outcomes. Participants will be randomly assigned to either keep taking aspirin or to receive a harmless tablet that looks the same but contains no active drug (placebo). The study will follow participants for several years, checking in at regular intervals.

During the follow‑up, researchers will record events such as cardiovascular death, fatal bleeding, intracranial bleeding, ischemic stroke, MI and other serious bleeding problems, as well as less severe issues like peptic ulcer, angina, and overall quality of life. The information collected will help decide if stopping aspirin is a safe option for older adults with stable heart disease.

The purpose of the study is to see whether lunsekimig can reduce the number of moderate to severe flare‑ups of the lung disease over a year. After enrollment, participants will be randomly assigned to one of the two groups and will attend regular clinic visits for injections, safety checks, and simple breathing tests over several months.

A flare‑up, or exacerbation, means a sudden worsening of breathing problems that often requires extra medication or a hospital visit. The term Forced Expiratory Volume in 1 second refers to a common breathing test that measures how much air a person can force out of their lungs in one second; it helps doctors track lung function. The eosinophilic pattern is identified by a blood test that shows higher eosinophil counts, which can influence how the disease behaves and responds to treatment.

The purpose of the study is to see whether a single dose of the medication can trigger migraine attacks in this group of women. After taking the tablet, participants will stay in a comfortable setting where their headache intensity, any occurrence of headache, heart rate (the number of beats per minute), and mean arterial pressure (a measure of overall blood pressure) will be recorded at regular intervals. Any side effects or unwanted symptoms that appear during the observation period will also be noted.

Participants may receive one of several study medicines: an oral tablet called ibrutinib, an oral capsule named zanubrutinib, an intravenous infusion of linvoseltamab, a subcutaneous injection (under the skin) of elranatamab, a subcutaneous injection of teclistamab, or a subcutaneous injection of talquetamab. Oral medicines are taken by mouth, while the infusion is given through a vein and the injections are placed just under the skin. Each medication is given at a specific dose that is determined by the study plan.

People are randomly assigned to receive one of the medicines and are followed for a period of time with regular clinic visits, blood tests, and health questionnaires. Throughout the study, researchers track how long participants live (called overall survival) and other health outcomes such as disease progression and quality of life, while also monitoring for any side effects.

The main goal of the trial is to see whether AGA2115 can increase bone mineral density (BMD) in the lumbar spine after one year of treatment. Adults with the condition will be randomly assigned to either the active drug or the placebo group and will be followed for about 12 months, with regular visits to check safety and measure bone density. The study will collect information on any side effects and overall health while participants continue their usual care.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

The primary aim is to evaluate how well this combination works in controlling the disease. Participants receive the injection and the capsule on a repeated schedule, typically every few weeks, and are followed for several months with regular doctor visits, blood tests, and imaging to check for disease activity and any side effects. The study continues until a predefined number of treatment cycles are completed or if a participant experiences significant toxicity that requires stopping the therapy.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

Participants are randomly assigned to receive either tablets containing 1800 mg of thiamine hydrochloride or matching placebo tablets for a period of four weeks. The trial is conducted in a double-blind manner, meaning that neither the participants nor the study staff know which tablets are being taken. Study visits include an initial assessment, regular check‑ins, and a final evaluation after the treatment period.

The purpose is to compare the effect of high dose thiamine with placebo on changes in fatigue as measured by the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional-Questionnaire global score from the start of the study to week 4.

Participants are randomly assigned to receive either a daily oral pill such as edoxaban or apixaban, an injectable medicine such as dalteparin, tinzaparin, enoxaparin, or rivaroxaban, or a placebo that looks the same but contains no active drug. Over several months, they will have regular check‑ups that may include simple scans of the lungs to confirm whether the clot has changed, and they will complete questionnaires about their daily well‑being. The study does not require any special procedures beyond the usual care for cancer and clot management.

The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

The purpose of the study is to assess the effectiveness and safety of OATD-01 over a 12-week period. Participants will be randomly assigned to receive either OATD-01 or a placebo, and neither the participants nor the researchers will know which treatment is being administered. Throughout the study, participants will undergo various assessments, including imaging tests like [18F]FDG PET/CT, to monitor changes in lung inflammation and overall health. The study aims to determine if OATD-01 can reduce the inflammation in the lungs and improve lung function and quality of life for those with active pulmonary sarcoidosis.

Participants will be closely monitored for any side effects or changes in their health during the study. The trial will also collect data on various health parameters, such as lung function tests and quality of life questionnaires, to evaluate the overall impact of the treatment. The study is expected to provide valuable insights into the potential benefits of OATD-01 for individuals with active pulmonary sarcoidosis.

People in the study will have either closed wounds, such as stitched cuts, or open wounds, such as small biopsy wounds made during the study. After treatment, the wounds will be followed over time while they heal, and the scars will be checked later. The study will also look at how safe the treatment is and whether any side effects occur, such as skin reactions or other body reactions. Some scars will also be looked at with medical pictures and ultrasound, which is a test that uses sound waves to create images inside the body.

Scar prevention is the main focus of this trial, and the study is designed to compare three verteporfin doses with saline in both open and closed wound types. The study will continue until the healing and scar checks are completed after treatment.

The purpose of the study is to determine if niraparib can help patients live longer without the disease getting worse, compared to temozolomide. Participants in the study will be randomly assigned to receive either niraparib or temozolomide. The study will monitor the participants over time to see how the treatments affect their health and the progression of their glioblastoma.

Throughout the study, researchers will also look at how the treatments impact overall survival, which means the length of time patients live after starting the treatment. Additionally, the study will assess the participants’ symptoms, quality of life, and any side effects they may experience. This information will help determine the safety and effectiveness of niraparib compared to temozolomide for treating this specific type of glioblastoma.

Each person will take the assigned tablet twice daily for about four months. During this time, they will complete a simple questionnaire called the Comprehensive Pain Assessment Tool Short Form (COMPAT‑SF) to record how much pain they feel, and another survey called the Short Form 36 (SF‑36) to evaluate overall well‑being. Blood samples will be taken to measure a protein linked to inflammation, known as high‑sensitivity C‑reactive protein (hs‑CRP), and the amount of opioid medication used will be expressed as oral morphine equivalents (OME). These checks are done at regular clinic visits, but no detailed technical procedures are required from the participants.

Safety is closely watched throughout the trial; doctors will look for any stomach irritation, bleeding, kidney changes, heart problems, or liver issues that might arise. Any unwanted effects are recorded and evaluated to ensure the treatment is well tolerated. The information gathered will help determine if the medication offers a meaningful benefit for people living with this condition.

The standard treatment in this study includes bevacizumab, oxaliplatin, fluorouracil, and calcium folinate. INCA33890 is given by vein, and the other medicines are also given as injections or infusions into a vein. People in the study are assigned by chance to one of two groups: one group receives INCA33890 with the standard treatment, and the other group receives placebo with the standard treatment. The study is blinded, which means the treatment group is not known to the people taking part or to the study team during the study.

After treatment starts, the study team follows how the cancer responds and how long the treatment helps keep the disease under control. The study also looks at how long people live and at side effects, which are unwanted health problems caused by a treatment.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of the study is to assess how safe the investigational drug is and to determine the appropriate dose when used alone or in combination with the hormone therapies.

Participants will first undergo screening tests, then begin taking the study medication in a series of visits. Depending on the study arm, they may receive an injection of the hormone blocker, a daily pill, or both, alongside the oral investigational drug. Throughout the study they will have regular check‑ups that include blood work, vital‑sign measurements, and heart rhythm checks to monitor safety. Treatment continues until the cancer shows growth, side effects become unacceptable, or the study ends.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The purpose of the study is to find out what doses of BMS-986517 are safe and how much people can tolerate in order to choose the best dose for future use, and to check if giving BMS-986517 at the chosen dose continues to be safe for people with specific cancers. The study will also monitor how often side effects occur, including serious side effects and those that might require stopping treatment. Additionally, the study will track whether tumors shrink and how long any responses last, as well as how the medication moves through and is processed by the body.

The study is divided into two parts. The first part focuses on testing different doses to determine which are safe and well tolerated. The second part uses the doses chosen from the first part to further evaluate safety in people with specific types of cancer. Participants will receive the medication through infusion and will be monitored for side effects during the first 21 days and throughout the treatment period, which can last up to 3 years from the first treatment, with additional monitoring for 30 days after the last treatment.

The purpose of this research is to test whether immunotherapy treatment, which usually works only for a small number of colorectal cancer patients, could be made effective for more patients when combined with other medications. The study will also look for biological markers that might help predict which patients will respond best to this treatment.

During the study, which may last up to 24 months, participants will receive a combination of these medications. The treatment involves taking temozolomide and capecitabine tablets daily, while ipilimumab and nivolumab are given through an intravenous infusion at scheduled times. Throughout the treatment, doctors will monitor how the cancer responds to these medications through regular medical check-ups and imaging tests.

The purpose of this research is to determine which medication provides better and safer conditions for placing the breathing tube in adult patients who need tracheal intubation during surgery. The study will look at how well each medication works and any possible side effects that may occur during or after the procedure.

During the study, patients will receive either remifentanil or rocuronium before the breathing tube is inserted. Doctors will monitor patients for any complications that might occur within 24 hours after the procedure, including effects on breathing, heart function, or discomfort in the throat. The medication doses are carefully calculated based on each patient’s weight, with remifentanil given at up to 4 micrograms per kilogram and rocuronium at up to 0.6 milligrams per kilogram.

At the start, pembrolizumab is given over a period of time, with regular medical checks during treatment. After treatment, the cancer is checked again with tests such as a CT scan, which is a special X-ray picture of the body, and an endoscopy, which is a thin tube test used to look inside the bowel. Based on these results, some people may go on to surgery, while others may be monitored closely without immediate surgery. The study also follows health over time to learn about possible side effects, recovery, and general well-being.

People in the study are assigned by chance to one of the two treatment groups, and neither the study team nor the participants know which treatment is being given. The treatment is taken as tablets over time, with regular study visits during the trial. During these visits, the study team checks for side effects and overall health, and asks about symptoms and daily well-being.

The trial is looking at adults with advanced kidney cancer who have already received treatment with PD-1/L1 and VEGF-TKI medicines, either one after the other or together. PD-1/L1 and VEGF-TKI are types of cancer medicines that act in different ways to slow tumor growth. The study follows participants while they receive treatment and for some time afterward to understand the effects of the medicine combination over time.

The study medication will be given through intramuscular injections, meaning the medicine is injected directly into muscles. Participants will receive either Xeomin or placebo injections over a period of 6 months. The treatment involves multiple injection sessions, with the medication being administered at specific intervals throughout the study period.

During the trial, participants will need to keep track of their headaches and migraine days using a headache diary. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of other migraine medications. The researchers will also track any side effects that may occur during the treatment period. The total study duration for each participant will be approximately 36 weeks.

The main purpose of this research is to determine if Xeomin is more effective than placebo in reducing the number of monthly migraine days. The study involves different doses of the medication, with participants receiving either Xeomin or placebo injections. The treatment period lasts for 6 months, during which participants will receive multiple injections.

The medication being tested, Xeomin, is a purified form of botulinum toxin that is free from complexing proteins. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of acute migraine medications. Throughout the study, participants will need to keep track of their migraine episodes and any changes in their condition.

Participants in the study will be randomly assigned to receive either BHV-7000 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about eight weeks, during which participants will take the medication or placebo daily. Researchers will monitor the participants to see if there is a reduction in the number of seizures they experience. The goal is to find out if BHV-7000 can help reduce seizures by at least 50% in those taking the medication compared to those taking the placebo.

Throughout the study, the safety and tolerability of BHV-7000 will be closely observed. This means researchers will keep track of any side effects or adverse reactions participants might experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for people with Refractory Focal Onset Epilepsy, potentially offering a new way to manage this challenging condition.

Participants in the study will receive either Barzolvolimab or a placebo, which is a substance that looks like the medication but does not contain any active ingredients. The study will last for several weeks, during which participants will receive regular doses of the medication or placebo. Throughout the study, participants will be monitored to assess changes in their urticaria symptoms, particularly focusing on the reduction of hives and itching. The main goal is to see if Barzolvolimab can significantly improve the condition compared to the placebo by the end of the study period.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased and reliable. The trial will also involve regular check-ups and assessments to track the progress and any potential side effects. The findings from this study could provide valuable insights into the effectiveness of Barzolvolimab as a treatment option for those suffering from Chronic Spontaneous Urticaria.

The purpose of this study is to determine how safe and tolerable Tolebrutinib is over a long period. Participants will take the medication orally, and the study will last for up to 36 months. During this time, researchers will monitor participants for any adverse events, which are unwanted effects that may occur during the study. The study will also look at how the medication affects the progression of disability in participants with MS and track any changes in the brain using Magnetic Resonance Imaging (MRI), a type of scan that provides detailed images of the brain.

In addition to Tolebrutinib, the study involves other substances like Anhydrous Cholestyramine, which is used to bind certain substances in the intestines, and Magnetic Resonance Imaging Contrast Media, which helps improve the clarity of MRI images. These substances are used to support the study’s objectives and ensure accurate monitoring of the participants’ health. The study aims to provide valuable information on the long-term use of Tolebrutinib in managing Multiple Sclerosis.

Participants in the study will be randomly assigned to receive either hydroxychloroquine sulfate or a placebo, which is a tablet that looks like the medication but does not contain any active ingredients. The study will monitor the participants throughout their pregnancy to observe any effects on pregnancy loss, premature birth, and other related outcomes. The medication will be taken orally in the form of film-coated tablets.

The trial will also assess the safety and tolerability of hydroxychloroquine sulfate for both the mother and the newborn. The study is expected to continue until the end of 2027, with participants being followed closely to gather comprehensive data on the effects of the treatment. The ultimate goal is to determine whether hydroxychloroquine sulfate can be a beneficial treatment option for improving pregnancy outcomes in women with antiphospholipid antibodies.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.

The purpose of the study is to evaluate how well GSK3862995B works compared with placebo in people with bronchiectasis. The study will look at whether the medication can reduce the number of times patients experience flare-ups of their condition over time. The study will also examine the safety of the medication, how the body’s immune system responds to it, and how the medication moves through and is processed by the body.

During this study, participants will receive repeated doses of either GSK3862995B or placebo over a period of time. The study is designed so that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo until the study is completed. Throughout the study, doctors will monitor how often participants experience flare-ups of their bronchiectasis, how long it takes before the first flare-up occurs, and how many severe flare-ups happen. The study is expected to continue until late 2027.